June 6, 2024Open Access

Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315)

Key Points

Key points are not available for this paper at this time.

Abstract

First-line therapy options in advanced cholangiocarcinoma (CCA) are based on the ABC-02 trial regimen (gemcitabine/cisplatin G/C). The NIFE trial examined nanoliposomal irinotecan/fluorouracil/leucovorin (nal-IRI/FU/LV) as alternative first-line therapy in advanced CCA.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Ettrich et al. (Thu,) studied this question.

synapsesocial.com/papers/68e65d00b6db6435875eb203 https://doi.org/https://doi.org/10.1200/jco.23.01566

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer2010 · 4,417 citations
2Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany2011 · 101 citations
3Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise2016 · 800 citations
4Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study2020 · 1,082 citations
5Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials2007 · 465 citations

Demander à l'IA

Bookmark

View Full Paper